Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypermutations in gliomas: a potential immunotherapy target.

Discovery medicine - 1 Feb 2017

Finocchiaro Gaetano, Langella Tiziana, Corbetta Cristina, Pellegatta Serena

Abstract excerpt

Checkpoint inhibitors, like ipilimumab, nivolumab, and pembrolizumab, have provided a breakthrough in cancer immunotherapy, such as in the treatment of melanoma and colorectal and lung cancer. The close relationship between the number of mutations (mutational load) and the response to checkpoint immunotherapy has been convincingly demonstrated in these cancers. Hypermutations in tumors are caused by environmental...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine
Share to MGMT gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Immunotherapy

Share to Mutation

Share to Temozolomide

Source

Identifiers

PMID: 28371614

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypermutations in gliomas: a potential immunotherapy target.PMID 28371614Read ↗

Hypermutation as a Potential Predictive Biomarker of Immunotherapy Efficacy in High-Grade Gliomas: A Broken Dream?Semantic proximity Read ↗

Mechanisms and therapeutic implications of hypermutation in gliomas.Semantic proximity Read ↗

Mutational burden and immune recognition of gliomas.Semantic proximity Read ↗

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutationsSemantic proximity Read ↗

Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.Semantic proximity Read ↗

The Temozolomide Mutational Signature: Mechanisms, Clinical Implications, and Therapeutic Opportunities in Primary Brain Tumor Management.Semantic proximity Read ↗

High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.Semantic proximity Read ↗

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read ↗

Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas.Semantic proximity Read ↗

The role of DNA mismatch repair in immunotherapy of human cancer.Semantic proximity Read ↗

Tumor mutational burden and immunotherapy in gliomasSemantic proximity Read ↗

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.